Pear Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 3/6
Pear Therapeutics has a total shareholder equity of $30.6M and total debt of $27.4M, which brings its debt-to-equity ratio to 89.7%. Its total assets and total liabilities are $95.1M and $64.5M respectively.
Belangrijke informatie
89.7%
Verhouding schuld/eigen vermogen
US$27.45m
Schuld
Rente dekkingsratio | n/a |
Contant | US$59.27m |
Aandelen | US$30.59m |
Totaal verplichtingen | US$64.54m |
Totaal activa | US$95.13m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch
Apr 17Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue
Aug 18Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic
Aug 03Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction
May 21Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets
Apr 04Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy
Jan 10Analyse van de financiële positie
Kortlopende schulden: PEAR.Q's short term assets ($73.0M) exceed its short term liabilities ($49.4M).
Langlopende schulden: PEAR.Q's short term assets ($73.0M) exceed its long term liabilities ($15.1M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: PEAR.Q has more cash than its total debt.
Schuld verminderen: Insufficient data to determine if PEAR.Q's debt to equity ratio has reduced over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: Insufficient data to determine if PEAR.Q has enough cash runway based on its current free cash flow.
Voorspelling contante baan: Insufficient data to determine if PEAR.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.